Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17130278.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cardiovascular risk factors after kidney transplantation are enhanced as a result of the chronic use of immunosuppressants. Tacrolimus with mycophenolate mofetil has become the most commonly used combination after kidney transplantation. Cardiovascular risk factors that are related to the use of this combined therapy have been analyzed in various clinical trials in comparison with other immunosuppressive therapies. This review summarizes the main results of these studies regarding arterial hypertension, lipid profile, posttransplantation diabetes, renal function, and even acute rejection rate. The aim is to characterize the cardiovascular risk profile of tacrolimus and mycophenolate mofetil association when compared with older and newer immunosuppressive associations.
Medical subject headings
- Cardiovascular Diseases
- Kidney Transplantation
- Mycophenolic Acid
- Tacrolimus